Table 4.

Univariate and multivariate analyses of clinical variables on intracranial progression -free survival

	Univariate HR (95% CI)	P	Multivariate HR (95% CI)	P
Age (≥60/< 60)	1.66 (0.78–3.54)	0.17
Gender (Female/Male)	0.64 (0.31–1.31)	0.204
Smoking status (Smoking/Never)	1.41 (0.65–3.06)	0.375
KPS (≥80/< 80)	0.34 (0.15–0.78)	0.006	0.34 (0.15–0.78)	0.011
EGFR mutation (exon 19 deletion/exon 21 L858R)	0.77 (0.39–1.52)	0.43
Co-existing BMs (yes/no)	0.89 (0.34–2.33)	0.804
Intracranial symptoms (yes/no)	1.40 (0.61–3.22)	0.413
LM at the time of NSCLC diagnosis (yes/no)	0.60 (0.21–1.72)	0.324
Treatment for LM
WBRT (yes/no)	0.51 (0.25–1.04)	0.052
EGFR-TKIs (yes/no)	0.45 (0.22–0.91)	0.019	0.442 (0.22–0.91)	0.027
WBRT+EGFR-TKIs/EGFR-TKIs alone	0.67 (0.27–1.67)	0.379

LM Leptomeningeal metastasis, KPS Karnofsky performance status, NSCLC Non-small-cell lung cancer, EGFR Epidermal growth factor receptor, TKI Tyrosine kinase inhibitor, WBRT Whole brain radiotherapy, ChT Chemotherapy, BMs Brain metastases